MODULATORY EFFECTS OF CHRONIC MUMIYO ADMINISTRATION ON HEMOSTATIC PROFILES: AN IN VIVO CANINE STUDY

This study evaluated the hemostatic impact of chronic Mumiyo (Shilajit) administration at a dosage of 100 mg/kg in a canine model. Five healthy adult dogs were monitored over a six-day period, with coagulation profiles established at baseline and sequentially on days 3, 5, and 6. Results indicated that Mumiyo administration induced a marked attenuation of procoagulant activity, evidenced by a statistically significant prolongation of whole blood clotting time, plasma recalcification time, thrombin time, and heparin time. A progressive increase in plasma tolerance to heparin suggests a potentiated sensitivity to anticoagulant modulation. Analysis of specific coagulation factors revealed a time-dependent divergence: Factor II levels rose monotonically, whereas Factor V exhibited an initial transient decline followed by a significant rebound elevation. Notably, while fibrinogen concentrations increased moderately, fibrinolytic activity underwent a concomitant decrease, signaling a retardation in clot degradation kinetics. Collectively, these data demonstrate that Mumiyo facilitates a systemic shift toward a hypocoagulable state, resulting in the formation of structurally "looser" and less stable fibrin networks. These findings underscore the potential antithrombotic properties of Mumiyo and necessitate further mechanistic investigations to determine its therapeutic viability in clinical hematology.